CD47 and neoplasm: Furthermore, the administration of anti-CD47 antibodies inhibited tumor growth and increased the survival of orthotopic immunodeficient mice transplanted with patient derived GBM cells, providing the first preclinical validation of CD47 as a therapeutic target in GBM (103).